In 2014, Obliteride participants raised $2.25 million for cancer research at Fred Hutch. One hundred percent of that money is now helping Fred Hutch investigators cure cancer faster.
2014 Obliteride funds are now at work across six research areas:
- More than a third of the funds are being invested in lung cancer research, which remains the deadliest form of cancer.
- Nearly 20% of the funds are supporting public health studies to help Fred Hutch researchers learn more about cancer in rural communities.
- We all know it’s important to eat right and exercise; 17% of 2014 funds are going to research connecting lifestyle and cancer risk.
- Nearly 20% of the funds are being invested in ovarian and breast cancer research, providing even more insight into these cancers afflicting [mostly] women.
- Infection remains a fierce thread to post-transplant survival. We’re investing 9% of Obliteride 2014 funds to better understand how to minimize post-transplant infection to increase survival rates and quality of life after a transplant.
- And finally, pediatric cancer research is also receiving a small percentage of funds from Obliteride 2014, with the goal of kicking off some novel research in pediatric oncology.
This picture reflects the breadth of research being done at Fred Hutch, and the multi-dimensional ways in which some investigators study lifestyle and exposure, while others zoom in on cellular biology. Collectively they’re piecing together the picture that helps us understand how to cure cancer faster.
Thank you for your relentless efforts to fundraise, pedal and talk about Fred Hutch research.